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Abstract The nuclear envelope is composed of two membranes 
deliminating a perinuclear space which displays functional 
properties similar to those of a Ca2+-storing compartment. 
ATP-driven Ca2+ uptake and InsP3-induced Ca
2+ release 
processes have been described in isolated nuclei. Recently, it 
was reported that cADP-ribose and InsP3 can trigger a 
nucleoplasmic Ca2+ increase. It was hypothesized that the inner 
nuclear membrane possesses Ca2+ channels that are regulated by 
ryanodine or InsP3. Radio-ligand binding assays and Western 
blot experiments were performed in order to investigate their 
presence in sheep cardiac and rat liver nuclear envelopes. 
Ryanodine receptors (RyR) were not detected in liver nuclear 
envelopes by either binding assay or Western blot analysis. 
However, cardiac nuclear envelopes were found to retain a very 
low level of specific ryanodine binding, which was not detected on 
immuno-blots obtained with three types of isoform-specific RyR 
antibodies. In contrast, nuclear InsP3-binding sites were 
consistently detected in both cardiac and liver nuclear envelopes. 
Altogether, these results provide evidence for the major 
contributor InsP3-gated Ca
2+ channels in control of Ca2+ 
release from the perinuclear space in liver and cardiac cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cell nucleus is delimited by the nuclear envelope (NE) 
that is made of two membranes (i.e. the outer nuclear mem-
brane, ONM; and the inner nuclear membrane, INM). Both 
membranes are thought to fuse at the nuclear pore complex 
(NPC), which controls the nucleo-cytoplasmic exchanges of 
macromolecules [1]. This double membrane system is sepa-
rated by a perinuclear space that is structurally and function-
ally related to the endoplasmic reticulum [2]. Some of the NE 
properties are similar to those of a Ca2+-storing compartment. 
A Ca2+-Mg2+-ATPase is present in the ONM [2], and is re-
sponsible for Ca2+ uptake into the perinuclear space [3-5]. 
Ca2+-binding proteins similar to calreticulin and calnexin 
have been located in the lumen of the perinuclear space 
[6,7]. Finally, ionic channels activated by inositol 1,4,5-tris-
phosphate (InsP3) are present in the ONM [8,9]. It has been 
reported that agonists promoting an increase of intracellular 
Ca2+ also triggered an increase of nucleoplasmic Ca2+ [10,11]. 
It was initially proposed that intranuclear Ca2+ variations 
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result from the diffusion of cytoplasmic Ca2+ through the 
NPC [10,11]. However, resting nucleo-cytoplasmic gradients 
of Ca2+ have already been described [12-15] and NPC is 
known to limit the propagation of Ca2+ waves through the 
nuclear envelope [16]. Malviya and co-workers have described 
the existence of InsP3 receptor (InsP3R) in the INM [17] and 
InsP3 was shown to trigger an increase of nucleoplasmic Ca
2+ 
[5,18]. Lately cyclic ADP-ribose (cADPR), a putative regula-
tor of the ryanodine receptor (RyR), was also reported to 
increase the nucleoplasmic Ca2+ in isolated liver nuclei [5]. 
However, biochemical evidence concerning the presence and 
the functional role of this specific family of intracellular Ca2+ 
channels are scant. In the present work, we have systemati-
cally investigated the presence of both nuclear RyR and 
InsP3R in cardiac and liver cells, using [
3H]ryanodine and 
[3H]InsP3-binding assays, as well as extensive Western blot 
analysis. Several microsomal membrane fractions were used 
as positive and negative controls for binding studies, and to 
confirm the specificity of antibodies raised against the various 
RyR isoforms. Our results indicate that InsP3 receptors are 
consistently present in cardiac and liver nuclear envelopes; 
although their density was lower than the density of InsP3-
binding sites measured in brain microsomal fractions. In con-
trast, our data show that RyR is clearly absent in the liver 
NE, while it is present in very low amount in the NE of 
cardiac cells, when compared to its density in cardiac SR 
membranes. 
2. Materials and methods 
2.1. Purification of nuclei and nuclear envelope 
Purification of nuclei and nuclear envelopes were routinely per-
formed on the same day. All procedural steps were done at 4°C. 
Sheep cardiac and rat liver nuclei were purified according to the pro-
cedure described by Howell and Lefebvre [19] and modified by Rous-
seau et al. [20]. In brief, fresh rat liver and sheep heart were homo-
genized in (25% w/v) ice cold buffer containing: 0.32 M sucrose, 3 mM 
MgCl2, 2 mM DTT, 20 mM K-HEPES (pH 7.2) and 50 uM Pefabloc, 
1 uM pepstatin, 1 uM leupeptin, 1 uM Na-ascorbate and 2.4 UI 
aprotinin with an Ultra-Turrax T25 at low speed with two 30-s bursts. 
The homogenate was filtered twice through two and four layers of 
cheesecloth, respectively, and then centrifuged at 3800 Xg (20 min). 
The pellet was resuspended in 2.4 M sucrose, 1 mM MgCl2, 2 mM 
DTT, 5 mM K-HEPES (pH 7.2) and centrifuged at 50000Xg (90 
min). The resulting pellet was gently resuspended in 150 mM KC1, 
20 mM MgCl2, 5 mM K-HEPES (pH 7.2), and centrifuged at 500Xg 
(20 min). Purified nuclei were finally resuspended in the same medium 
or in 0.3 M sucrose 1 mM MgCl2, 5 mM K-HEPES (pH 7.2) for 
storage at -85°C. 
The NE were prepared from nuclei suspensions sonicated by two 30 
seconds bursts (W-375 sonicator, Heat System Ultrasonics Inc.) sep-
arated by one minute at 4°C. Chromatin was digested with DNase (10 
ug/ml) and RNase (5 ug/ml) during 30 min at 30°C and nuclear 
membranes were washed with 1.8 M NaCl in order to prevent his-
tones self aggregation [7]. Nuclear membranes were sedimented by a 
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final centrifugation (100 000 Xg, 45 min), resuspended in either 50 
mM KC1, 5 mM K-HEPES (pH 7.2) or 0.3 M sucrose 1 mM MgCl2, 
5 mM K-HEPES (pH 7.2) and kept at -85°C. The protein concen-
tration was determined according to Lowry et al. [21], using bovine 
serum albumin as standard. 
2.2. Preparation of cardiac and skeletal SR, as well as brain and 
liver microsomal fractions 
Membrane fractions enriched in sarcoplasmic reticulum (SR) de-
rived from rabbit skeletal, canine diaphragm, and canine cardiac 
muscles were prepared according to Rousseau et al. [22], Picher et 
al. [23] and Decrouy et al. [24], respectively. Canine brain microsomes 
(BM) were prepared according to reference [25]. Freshly isolated brain 
from which cerebellum has been removed was homogenized with an 
Ultra-Turrax T25 at low speed with two 30 seconds bursts, in the 
same ice cold buffer as described for the nuclei. The homogenate 
was filtered twice through two and four layers of cheesecloth, respec-
tively, and centrifuged at 3800Xg (20 min). The resulting supernatant 
was centrifuged at 5000Xg (10 min) and then at lOOOOOXg (45 min). 
The final pellet containing the brain microsomal fraction was resus-
pended in either 150 mM KC1, 5 mM K-HEPES pH 7.2 or 0.3 M 
sucrose, 1 mM MgCl2, 5 mM K-HEPES (pH 7.2) and kept at -85°C 
until used. The same procedure was used to prepare rat liver micro-
somal fractions. 
2.3. [sH]Ryanodine and [:' H]: Ins P3-binding assays 
Ryanodine-binding assays were performed on NE vesicles as de-
scribed previously [22] with sheep cardiac SR as positive controls. 
Briefly, vesicles (500 ug of proteins) were incubated with 
[3H]ryanodine (2619.6 GBq/mmol) for 90 min at 37°C in the presence 
of 40 uM free Ca2+ with or without an excess of non-radioactive 
ryanodine. The mixture was then centrifuged twice to remove non-
specific binding and the pellet radioactivity was determined by liquid 
scintillation. Specific [3H]ryanodine (expressed in fmol mg - 1 protein) 
was calculated by subtracting non-specific binding (5 nM 
[3H]ryanodine+5 uM ryanodine) from total binding (5 nM 
[3H]ryanodine alone). [3H]InsP3 binding was performed as described 
previously [26]. Membrane vesicles (500 ug of proteins) were incu-
bated 30 min at 4°C in Tris-HCl 25 mM (pH 8.5), KC1 100 mM, 
NaCl 20 mM, KH 2P0 4 5 mM, EDTA 1 mM and BSA 0.1% (w/v) 
in presence of 10 nM [3H]InsP3 (770 GBq/mmol) or 10 nM [
3H]InsP3 
plus 10 (xM InsP3. The membrane suspensions were centrifuged and 
the pellet radioactivity was determined by liquid scintillation. Specific 
[3H]InsP3 binding (expressed in fmol mg - 1 protein) was calculated by 
subtracting non-specific from total counts. 
2.4. SDS-polyacrylamide gel electrophoresis and Western blot analysis 
Membrane samples were solubilized in 2% SDS and proteins were 
separated on 10% SDS-PAGE under reducing conditions (p-mercap-
toethanol 5 mM). All gels were run in parallel with broad molecular 
weight standards provided by BioRad. Proteins were stained by gel 
incubation in ethanol 50% (v/v), acetic acid 10% (v/v) and Coomassie 
blue 0.1% (w/v). Western blot analysis of the different membrane 
fractions was performed as follows: the proteins were electrotrans-
ferred onto a PVDF-membrane (BioRad) overnight at 35 V (4°C). 
The membranes were then incubated in the presence of a monoclonal 
mouse antibody raised against Lamin Bl [27]. Nuclei and microsomal 
preparations were also probed for the presence of protein specific for 
the NPC, using a monoclonal antibody (M Ab414) which recognizes a 
protein of 62 kDa [28]. In order to investigate the presence of RyRs, 
various membrane fractions were electrophoresed on 6% SDS-PAGE 
and transferred to nitrocellulose membranes at 30 V overnight at 4°C. 
The nitrocellulose membranes were washed 15 min in 200 mM Tris, 
1.4 M NaCl+0.1% Tween 20, pH 7.6 (TBS-T), blocked with 5% non-
fat dry milk in TBS-T and incubated with antibodies against various 
RyR isoforms. Antibodies against RyR I and RyR III isoforms were 
generous gifts from Dr. G. Meissner and Dr. W. Chen, respectively. 
Revelations were performed by enhanced chemiluminescence (Boeh-
ringer-Mannheim) or horseradish peroxidase (BioRad) using protein 
A or specific IgG as a secondary antibody. 
2.5. Preparation of anti-cardiac ryanodine receptor polyclonal 
antibodies 
The cardiac ryanodine receptor complex (RyR2) was solubilized 
and purified to homogeneity by sucrose gradients and heparin-Sephar-
ose affinity chromatography [22]. The proteins were concentrated on 
AMICON prior to deposition on immobilon fragments. Male rabbits 
were immunized by intrasplenic insertion of nanogram quantities of 
the purified canine cardiac RyR2 absorbed to small immobilon frag-
ments according to [29] with some modifications. The rabbits were 
anesthetized with 1% halothane and the spleen was carefully exposed 
by a 20 mm cutaneous incision, followed by incision of the abdominal 
wall and the peritoneum. The splenic capsule was punctured with a 
needle and the micro-fragment of immobilon (2 mm2) inserted under 
the capsule. Bleeding was stopped by application of a 3 mm2 SUR-
GICEL patch. After intrasplenic deposition of the antigen, the ab-
dominal wall and the skin were sutured separately. Intrasplenic im-
munization was repeated twice within a month without the use of 
adjuvant. Cardiac anti-RyR2 antibodies were detected in rabbit serum 
two weeks after the second intrasplenic deposition by a standard 
ELISA procedure. Then the immunological response was improved 
by four successive immunizations performed once-a-month. The first 
immunization was a subcutaneous implant, while the others were 
simultaneous subcutaneous (150 jxl) and intramuscular (50 ul) injec-
tions. The presence of cardiac anti-RyR2 antibodies in the serum was 
confirmed by immuno-blot assays on purified RyR2 and cardiac heavy 
SR membranes. 
3. Results 
The first part of this work was aimed at the characterization 
of the nuclear envelope (NE) fractions. Thus, in Fig. 1A, the 
protein profiles of liver and cardiac NE (lanes 2 and 4) were 
compared to the profile of liver microsomal and cardiac SR 
fractions (lanes 1 and 3), respectively. Although these Coo-
massie blue stainings of membrane fractions are likely to re-
veal protein bands of similar relative molecular weight, the 
nuclear and microsomal protein profiles displayed major dif-
ferences. It should be further noted that the protein profile 
derived from liver and cardiac NE also displayed major dis-
similarities. Indeed, cardiac NE harboured bands in the 200, 
97 and 45-kDa regions that were not detected in the liver NE. 
To further characterize the NE, a typical intranuclear mem-
brane (INM) marker was used. Lamins A, B, C proteins are 
known to form a highly organized nucleoplasmic network 
Table 1 
[3H]Ryanodine and [3H]InsP3 specific binding in nuclear envelopes and microsomal fractions 
Membrane fractions [3H]Ryanodine 
(fmol/mg of protein) 
[3H]InsP3 
(fmol/mg of protein) 
Liver nuclear envelope 
Cardiac nuclear envelope 
Cardiac sarcoplasmic reticulum 
Brain microsomes 
0.5 ±1.9 
21.9±1.7 
1972 ±36.8 
34" 
(«=12) 
(« = 6) 
(n = 6) 
187 ±6.7 
33.5 ±4.4 
0.57 ±0.38 
214.5 ±16.4 
(n = 6) 
(« = 6) 
(» = 3) 
(« = 6) 
The purification of the different membrane fractions and subsequent binding assays were performed as indicated in Section 2. The values given for 
[3H]ryanodine and [3H]InsP3 binding are expressed in fmol mg
- 1 protein and represent the mean ± S.E.M. of (n) independent experiments. 
"From Padua et al., 1994 [33]. 
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involved in nuclear structure and dynamics [30]. Lamins A 
and C are distributed across the whole nucleoplasm [31] while 
lamin B tightly interacts with a complex receptor that is lo-
cated in the inner nuclear membrane [32]. Lamin B is consid-
ered to be a good marker of INM [20,27]. Western blot ex-
periments using a monoclonal anti-lamin Bl antibody were 
performed in order to investigate the presence of lamin B in 
NE, microsomal and SR membrane fractions. The results are 
given in Fig. IB. The antibody mainly recognized a 67-kDa 
Fig. 1. Protein profile and immuno-detection of Lamin Bl in nu-
clear and microsomal membrane fractions derived from liver and 
cardiac cells. (A) Coomassie blue staining of the protein profile (20 
|Xg of protein) from crude liver microsomes (lane 1), liver nuclear 
envelope (lane 2) cardiac heavy SR (lane 3) and cardiac nuclear en-
velope (lane 4) loaded on 10% SDS-PAGE. (B) Western blot analy-
sis of the same membrane fractions, using a monoclonal anti-lamin 
Bl antibody as indicated in Section 2. (C) Immuno-detection of the 
62 kDa protein (p62) of NPC using the monoclonal antibody 
MAb414: liver nuclei (lane 1'), crude liver microsomes (lane 2') car-
diac nuclei (lane 3') and cardiac heavy SR (lane 4'). The p62 was 
absent from liver microsomal and cardiac SR fractions (lane 2' and 
4', respectively). In contrast, liver and cardiac nuclei preparations 
were enriched in p62 (lanes 1' and 3'), thus they were used to pre-
pare the corresponding NE to perform subsequent binding and im-
munological assays. 
protein in both liver and cardiac NE (lanes 2 and 4, respec-
tively). This protein was neither detected in liver microsomal 
(lane 1), nor in cardiac SR (lane 3) fractions. We have con-
sistently observed that the relative signal density generated by 
the anti-lamin Bl antibody was higher in liver than in cardiac 
NE, even though equivalent amounts of liver and cardiac 
proteins were loaded on the gel. This is likely to result from 
a higher lamin Bl expression in liver NE. Fig. 1C shows that 
the liver and cardiac nuclei fractions were both enriched in a 
62-kDa protein known to be associated to the NPC [28] (lanes 
1' and 3', respectively). In contrast, the liver microsomal and 
cardiac SR fractions were totally deprived of such protein 
band (lanes 2' and 4'). Altogether, these results indicate that 
it is possible to prepare enriched NE fractions from rat liver 
or sheep cardiac nuclei. Moreover, these nuclear membrane 
fractions display the presence of a typical NE and INM 
markers p62 of the NPC and lamin Bl, which were never 
detected in crude liver microsomal or in cardiac SR fractions. 
3.1. Detection of nuclear ryanodine receptors 
We have used experimental conditions that have been pre-
viously used for an efficient detection of specific 
[3H]ryanodine-binding sites in skeletal, cardiac and atrial SR 
[22,24]. In the SR membrane preparations ryanodine binds to 
its receptor with an estimated K& of 2.5 nM. [3H]ryanodine-
binding assays were performed on membrane vesicles derived 
from liver and cardiac NEs and were compared to the binding 
level in cardiac SR fractions as a positive control (Table 1). 
[3H]ryanodine binding was not performed on brain microso-
mal fraction in this study. However, our brain microsomal 
fractions and binding conditions (i.e. high ionic strength) 
were similar to the one described by Padua et al. [33]. Thus, 
we assumed that the [3H]ryanodine binding level of our brain 
microsomal fraction was equivalent (i.e. 34 fmol mg_ 1 pro-
tein) to the one determined by these authors. NEs purified 
from cardiac cells retained 21.9±1.7 fmol [3H]ryanodine 
mg_ 1 protein (n = 6). This value was low when compared to 
cardiac SR fraction (1972 ±36 fmol mg_ 1 protein, n-6) but 
was very close to the one we initially determined (20 fmol 
mg_ 1 protein) on cardiac nuclei fraction [20]. As discussed 
earlier, we cannot exclude that cardiac NE ryanodine binding 
originated from a residual contamination (less than 1.5%) of 
nuclei by heavy SR vesicles [20]. Surprisingly, the 
[3H]ryanodine binding to liver NE was negligible (0.5 ±1.9 
fmol mg - 1 protein, « = 6). Moreover, no specific ryanodine 
binding was detected on intact liver nuclei (data not shown) 
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which strongly suggest the absence of specific ryanodine-bind-
ing sites in the NE of liver cells. 
Western blot analysis, using antibodies directed against var-
ious ryanodine receptor isoform - RyRi, RyR2 and RyR3 -
were performed in order to reveal the putative presence of 
RyR in the NEs of liver and cardiac cells. Fig. 2A indicates 
that the RyRi isoform was neither detected in liver (lane 1) 
nor in cardiac (lane 2) NEs. Furthermore, the RyRi antibody 
did not recognize the RyR2 isoform from cardiac SR (lane 3), 
but clearly detected the RyRi isoform in skeletal SR mem-
brane (lane 4), indicating that this antibody efficiently discrim-
inated between RyRi and RyR2 isoforms. Fig. 2B shows that 
the anti-RyR2 antibody did not detect any protein band 
(RyR2) in both liver (lane 1) and cardiac (lane 2) nuclear 
Fig. 2. Western blot analysis of the various RyR isoforms in nuclear 
envelopes and SR membrane fractions. (A) Membrane proteins of 
rat liver NE (lane 1), sheep cardiac NE (lane 2), canine cardiac SR 
(lane 3) and rabbit skeletal SR fractions (lane 4) were loaded and 
separated on 6% SDS-PAGE, transferred on nitrocellulose mem-
branes and incubated in the presence of anti RyRi antibodies. The 
RyRi isoform was only detected in skeletal SR, as a single protein 
band of high molecular weight. (B) Same membrane fractions as in 
A probed with Anti RyR2 antibodies. Note the absence of staining 
in the liver and cardiac NE (lanes 1 and 2), as well as in the skele-
tal SR (lane 4) fraction from fast-twitch muscles. A single band was 
detected in cardiac SR (lane 3). (C) Same membrane fraction as 
above in lanes 1, 2 and 3, while lane 4 contained SR membrane 
fractions derived from canine diaphragm muscles, used as positive 
control for the RVR3 isoform. No specific staining was detected in 
the liver and cardiac NE (lanes 1 and 2), as well as in cardiac SR 
(lane 3), although the presence of a smear probably due to the pres-
ence of DNA was observed in lane 1. Note the high molecular 
weight band stained in the SR membrane from canine diaphragm 
(lane 4). 
membranes, even when 80 (j.g of proteins were loaded instead 
of 20 u.g, or in skeletal SR (lane 4). Under identical condi-
tions, the anti-RyR2 antibody recognized a single protein 
band in the cardiac SR (lane 3). A third set of western blot 
analysis was performed using an other antibody raised against 
a specific sequence of type III RyR. This isoform was previ-
ously detected in the terminal cisternae (junctional SR) from 
various mammalian skeletal muscles, and consistently in the 
diaphragm from different species [34]. Fig. 2C shows that the 
anti-RyR3 antibody did not recognize any protein band in 
liver (lane 1) and cardiac (lane 2) NEs, as well as in the 
cardiac SR fraction (lane 3). However, this antibody detected 
a high molecular weight protein band in canine diaphragm 
preparations known to be enriched in RyR3 isoform (lane 
4); as well as in the SR fractions derived from rabbit hind 
limb rabbit skeletal muscles (data not illustrated). These re-
sults indicate that the RyR isoforms I, II and III are unlikely 
to reside in the nuclear envelope of liver and cardiac cells. If 
so, it must be below detectable level since similar results were 
obtained on freshly isolated nuclei (data not illustrated). 
3.2. Detection of nuclear InsP$ receptors 
In the following experiments, we investigated the putative 
presence of InsPsR in cardiac and liver NE. We have deter-
mined the [3H]InsP3 binding ability of these two types of 
nuclear membrane fractions, while brain microsomal (BM) 
and cardiac SR vesicles were used as positive and negative 
controls, respectively. Table 1 indicates that BM bound 
214 ±16.8 fmol mg_ 1 protein, while cardiac SR did not ex-
hibit any significant [3H]InsP3 binding (0.57 ±0.38 fmol mg_ 1 
protein). Liver and cardiac nuclear envelopes retained 187 ±6 
fmol mg_ 1 protein and 33 ±4 fmol mg_ 1 protein, respectively. 
These results demonstrate the existence of InsPsR in both 
cardiac and liver nuclei. InsP3-binding sites had already 
been described in the NE of liver cells [4]. They were located 
to the inner nuclear membrane and were correlated with the 
immuno-detection of a nuclear InsPsR [17]. 
4. Discussion 
The present study shows direct biochemical and immuno-
logical evidences of the absence of ryanodine receptors in NE 
of liver nuclei, and minimizes the putative role of these recep-
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tors in cardiac NE. Moreover, we provide new evidence that 
InsP3Rs could be involved in the control of nuclear Ca
2+ in 
cardiac and liver cells, as shown previously in oocytes nuclei 
[8,9]. 
During the last decade, numerous studies have demon-
strated that the nuclear envelope is involved in the regulation 
of nucleoplasmic ion concentrations [35]. Several ionic perme-
abilities have been characterized in both the inner and the 
outer nuclear membranes of different cell types (reviewed in 
[36]). The existence of nuclear Ca2+ channels was postulated 
from the pioneer works of [3] and [4] who, respectively, 
showed an InsP3-induced Ca2+ release from isolated liver nu-
clei, and the presence of InsP3-binding sites in the nucleus. 
InsP3-gated channels have recently been functionally charac-
terized in the outer nuclear membrane of Xenopus oocytes 
[8,9]. In liver nuclei, InsP3-binding sites have been located in 
the inner nuclear membrane [17] and a InsP3-induced Ca2+ 
release from the perinuclear space to the nucleoplasm was 
measured [5]. In the present study, we have confirmed the 
presence of InsP3-binding sites in the nuclear envelope of liver 
cells. Significant InsP3 specific binding was also found in the 
NE of cardiac cells, although its relative density was six times 
lower than in the liver NE. These findings confirm the pre-
vious immuno-localization of InsPsR isoform I in the perinu-
clear region of rat liver [37]. However, the amount of InsP3 
binding to the cardiac NE reported herein (33 fmol/mg of 
protein, Table 1) is relatively higher than previously deter-
mined (12 fmol/mg of protein) on crude cardiac nuclei [20]. 
Recently cADPR was reported to trigger Ca2+ release from 
the perinuclear space of liver nuclei via RyRs [5]. Our present 
results do not support this conclusion. Although several find-
ings indicate that cADPR regulates intracellular Ca2+ release 
[38] it is still a matter of debate whether cADPR directly 
triggers the opening of RyR [39]. In the present study, we 
clearly demonstrated that liver nuclei possess no ryanodine 
receptor. This is also supported by the fact that messenger 
RNAs encoding RyaR isoforms I, II or III are not detected 
in liver extracts [40] and that ryanodine does not induce Ca2+ 
release from isolated nuclei [41]. It should be further men-
tioned that NAD+, the metabolic precursor of cADPR, stim-
ulates Ca2+-uptake by the nuclear envelope [42]. These data 
and the ones presented herein indicate that the cADPR-trig-
gered effects in liver nuclei is likely to be mediated through a 
mechanism that does not depend on a high molecular weight 
nuclear RyR. Furthermore, no trace of specific immuno-stain-
ing was detected in the cardiac NE using three different iso-
form specific RyR antibodies despite the low level of 
[3H]ryanodine binding that might be due to a residual con-
tamination of NE by heavy SR membrane vesicles as dis-
cussed previously [20]. One may point out that cADPR has 
been reported to interact with 100 and 140-kDa proteins, of 
which neither the functions nor the cellular distribution of 
which have been defined [43]. In these conditions, it is tempt-
ing to postulate that cADPR may trigger Ca2+ release in 
the cell nucleus through the activation of an unknown and 
somewhat more complex pathway. Nevertheless, in cardiac 
cells, no Ca2+ sparks which originate from clusters of SR-
RyRs, have been reported to occur in close vicinity of the 
NE [44]. 
Intracellular Ca2+ regulation represents a signalling path-
way through which the cell coordinates major biological func-
tions [45]. Ca2+ has been involved in the regulation of typical 
nuclear functions such as gene expression, DNA breakdown, 
repair and replication through its binding to calmodulin [46]. 
Furthermore, intracellular Ca2+ transients are often associ-
ated with cell-cycle events such as DNA condensation and 
nuclear envelope breakdown [47] and it has been suggested 
that InsP3 may be involved in the early events triggering 
Ca2+-regulated nuclear envelope breakdown [48]. The contri-
bution of the InsP3 pathway has also been investigated in the 
case of post-mitotic nuclear envelope reformation. On the 
basis of the works of [49,50], it appears that the activation 
of InsP3R located in nuclear envelope vesicules and the sub-
sequent release of Ca2+ from these vesicules represents a fun-
damental step preceding the fusion of nuclear vesicules and 
nuclear envelope reformation. Recently, the expression of a c-
fos - a well known Ca2+-regulated gene - was shown to be 
differentially regulated upon increasing cytosolic or nucleo-
plasmic Ca2+ [51]. This indicates that Ca2+ involved in nucle-
oplasmic Ca2+ increase may originate from different sites. It is 
accepted that the increase of nucleoplasmic Ca2+ can result 
from the diffusion of cytosolic Ca2+ through the NPCs, since 
NPCs restrict but do not prevent Ca2+ diffusion [16]. How-
ever, alternative pathways should be considered. Phosphatid-
yl-inositol 4,5 bisphosphate (PIP2) is located in the nuclear 
envelope [52]. Phosphoinositidases C (pi, 54) are also present 
in the nucleus [53,54]. Intranuclear production of InsP3 from 
PIP2 hydrolysis could activate the nuclear InsPsR, which 
could also be stimulated by nuclear protein kinase C [42,55]. 
The current challenge is to demonstrate that ligand-gated nu-
clear ionic channels may play an important role in NE func-
tions. 
Lately, Jayaraman and Marks [56] have shown the T cells 
deficient in InsPsR, are resistant to apoptosis induced by dex-
amethasone. This property was reversed by pharmacologically 
raising cytoplasmic Ca2+ levels. Moreover, receptor mediated 
apoptosis can be induced in Ca2+-free media. These findings 
suggest that intracellular Ca2+ release, via InsPsR, is a critical 
step controlling programmed cell death. Several reports show 
that the Ca2+ content of perinuclear space could also control 
the nucleo-cytoplasmic traffic of macromolecules. Indeed, clo-
sure of the nuclear pore complex and subsequent blockade of 
nucleo-cytoplasmic traffic was observed after emptying the 
perinuclear space of its Ca2+ content [57-59]. This shows 
that the elucidation of the mechanism(s) of regulation of nu-
clear Ca2+ fluxes is of primary importance in molecular cell 
physiology. 
In conclusion, according to the data obtained in the present 
study, the odds would be in favor of a major role for InsP3R, 
over the putative implication of RyRs, in controlling Ca2+ 
efflux from the perinuclear space. It is worth noticing that 
in a recent study using Ca2+ confocal imaging to analyse 
rapid and slow Ca2+ waves as well as pharmacological assays, 
Jainovish and Liberona [60] came up with the same conclu-
sions regarding the absence of RyR and the presence of 
InsPsR in rat myotubes nuclei. 
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